Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 4/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24732099 | 0.85 | HRH4 (0.73) | HRH4TAAR1HRH3HRH2 | |
| SCHEMBL224745 | 0.79 | TAAR1 (1.00) | HRH4TAAR1HRH3 | |
| SCHEMBL29396933 | 0.79 | HRH4 (0.65) | HRH4HRH3MEN1KMT2AHDAC1 | |
| SCHEMBL4897840 | 0.78 | TAAR1 (0.67) | HRH4TAAR1HRH3 | |
| SCHEMBL2536900 | 0.76 | HRH3 (0.93) | HRH4TAAR1HRH3HRH2 | |
| SCHEMBL13073926 | 0.74 | HRH3 (0.77) | HRH4HRH3MEN1KMT2A | |
| SCHEMBL3934417 | 0.74 | HRH3 (0.61) | HRH4HRH3MEN1KMT2AHRH2 | |
| SCHEMBL1034848 | 0.73 | HRH3 (1.00) | HRH4TAAR1HRH3 | |
| SCHEMBL22894793 | 0.73 | HRH4 (0.57) | HRH4HRH3MEN1KMT2A | |
| SCHEMBL25634469 | 0.73 | HRH4 (0.57) | HRH4HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| CN-110003200-B | P2X7 modulators | 詹森药业有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
| US-20200325138-A1 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-15 | — | — | US | disclosed |
| US-10703749-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-07 | — | — | US | disclosed |
| EP-2970267-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-24 | — | — | EP | disclosed |
| US-20160376271-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV | 2016-12-29 | — | — | US | disclosed |
| US-9464084-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-11 | — | — | US | disclosed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| EP-2970267-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20150322062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-12 | — | — | US | disclosed |
| US-9066946-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| WO-2014152604-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275015-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325138-A1 | P2X7 Modulators | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-20160376271-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | HRH4 2543/4885TAAR1 4111/4885HRH3 2365/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | HRH4 2441/4885TAAR1 4708/4885HRH3 3867/4885 |
| US-20160039809-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RX5 | HRH4 1082/4885TAAR1 770/4885HRH3 1157/4885 |
| US-20150322062-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-10703749-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
| US-20140275015-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | HRH4 1162/4885TAAR1 894/4885HRH3 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.